Factor VIII inhibitors in hemophilia A treated with emicizumab
Por um escritor misterioso
Descrição
ADDING MULTIMEDIA FDA Approves Genentech's HEMLIBRA (emicizumab
Use of chromogenic Factor VIII activity determination in
NHF GUIDELINES Bundle - Emergency Management of Bleeding Disorders
PDF] Laboratory monitoring of hemophilia A treatments: new
Longitudinal dynamic changes in factor VIII inhibitor titers in
Emicizumab for the treatment of acquired hemophilia A - ScienceDirect
PDF) Emicizumab Prophylaxis in Hemophilia A with Inhibitors
China approves imports of Roche's hemophilia treatment Hemlibra
Emicizumab Decreases Factor VIII Inhibitor Titers in Hemophilia A
Management of bleeding events and invasive procedures in patients
A Molecular Revolution in the Treatment of Hemophilia: Molecular
Emicizumab Lowers Bleeding Rates in Children With Hemophilia A and
de
por adulto (o preço varia de acordo com o tamanho do grupo)